Recruiting

Testing a new kidney cancer medicine alone and with other treatments

Plain-English translation of NCT07227415 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.

What is this trial?

This trial is testing a new medication called for people with advanced kidney cancer that has either spread to nearby tissues or to other parts of the body. The study will see how safe this medication is and how well it works when given by itself or combined with other approved cancer treatments. Researchers will track how participants respond and what side effects occur.

Kidney cancer that has spread or cannot be treated with surgery remains difficult to treat, and doctors need new options. This trial explores whether this new medication, alone or combined with existing therapies, could help patients with advanced kidney cancer live longer and better.

Do you qualify?

You likely qualify if…

you are 18 years old or older
you have been diagnosed with advanced or metastatic kidney cancer that has not been treated with systemic therapy before
you have at least one measurable tumor or lesion that has not been treated
your heart, liver, kidneys, and blood counts are functioning adequately
your overall health and ability to perform daily activities are good enough for treatment (ECOG score 0 or 1)

You likely don't qualify if…

you have active cancer that has spread to your brain, spinal cord, or brain lining
you have a history of another cancer diagnosed within the past 3 years
you have an active autoimmune disease that requires ongoing treatment
you have had a major surgery or severe injury within the past 4 weeks, or surgery is planned during the study
you have a history of serious bleeding problems or recent severe gastrointestinal bleeding

What participation looks like

Participants will receive the medication through intravenous infusions at a clinical study site where trained medical staff will monitor them. Depending on which study group you're assigned to, you may receive the new medication alone or combined with one of two other approved cancer drugs. The study involves regular clinic visits for treatment and follow-up care, where doctors will assess how you're responding and watch for any side effects.

AI-generated summary from trial data · Jul 8, 2026 · Not medical advice

Testing a new kidney cancer medicine alone and with other treatments

What is this trial?

Do you qualify?

What participation looks like

Trial locations(128 sites)